Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPZE1 challenge study in healthy adults
NCT05461131Phase 2Completed
- Sponsor
- ILiAD Biotechnologies
- Start
- Jun 2022
- Primary completion
- Jul 2023
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pertussis comparing BPZE1 with Placebo (2 arms). Primary endpoint: Number of Participants Colonized Following Virulent Challenge at Day 14. Started Jun 2022; status: completed.
02
Drugs
BPZE1
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT05461131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05461131.